0001062993-24-013820.txt : 20240715
0001062993-24-013820.hdr.sgml : 20240715
20240715172925
ACCESSION NUMBER: 0001062993-24-013820
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240711
FILED AS OF DATE: 20240715
DATE AS OF CHANGE: 20240715
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rottinghaus Scott T.
CENTRAL INDEX KEY: 0001942407
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35839
FILM NUMBER: 241118115
MAIL ADDRESS:
STREET 1: C/O ENANTA PHARMACEUTICALS, INC.
STREET 2: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001177648
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617 607 0800
MAIL ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-07-11
0001177648
ENANTA PHARMACEUTICALS INC
ENTA
0001942407
Rottinghaus Scott T.
C/O ENANTA PHARMACEUTICALS, INC.
500 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Chief Medical Officer
1
Common Stock
2024-07-11
4
S
0
4299
15.07
D
23988
D
Common Stock
2024-07-12
4
S
0
2271
15.04
D
21717
D
Common Stock
2024-07-15
4
M
0
5375
8.99
A
27092
D
Common Stock
2024-07-15
4
S
0
5375
17.08
D
21717
D
Stock Option (Right to Buy)
8.99
2024-07-15
4
M
0
5375
0
D
2033-11-22
Common Stock
5375
80625
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.155, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.21, inclusive.
The option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2-4 above.
/s/ Paul J. Mellett as attorney-in-fact
2024-07-15